Akebia Therapeutics Announces Publication of Pre-specified Analyses on Vadadustat from Global Phase 3 Clinical Program in Journal of the American Society of Nephrology

Akebia Therapeutics announced the publication of Phase 3 trial analyses of vadadustat (Vafseo) in the Journal of the American Society of Nephrology, revealing efficacy and safety profiles similar to darbepoetin alfa in dialysis-dependent CKD patients both in the U.S. and internationally. However, the analysis indicated a higher risk of major adverse cardiovascular events (MACE) with vadadustat in non-dialysis-dependent CKD patients outside the U.S., which may impact treatment decisions despite Vafseo's FDA approval for dialysis-requiring patients.

Analysis

Akebia Therapeutics (AKBA) announced the publication of pre-specified analyses from its vadadustat global phase 3 clinical program in the Journal of the American Society of Nephrology, lending credibility to the data. For Akebia's FDA-approved Vafseo (vadadustat), indicated for adults with dialysis-dependent chronic kidney disease (DD-CKD) for at least three months, these analyses showed similar safety and efficacy profiles compared to darbepoetin alfa in both U.S. and international DD-CKD patient subgroups. This supports its current approved use. However, the analyses also highlighted that for non-dialysis-dependent (NDD-CKD) patients outside the U.S., vadadustat was associated with a higher risk of major adverse cardiovascular events (MACE) compared to darbepoetin alfa; Vafseo is explicitly not indicated for NDD-CKD patients due to increased risks of mortality and other serious adverse events in this population, as noted in its prescribing information which includes a boxed warning for increased risk of death, MI, stroke, and thrombotic events. Despite Vafseo's approval in 37 countries, these significant safety concerns and its limited indication could restrict market penetration. Reinforcing a cautious outlook, AKBA insiders have exclusively sold stock over the past six months, with 7 sales and zero purchases, including significant sales by the CEO (190,659 shares for ~$387,853) and other C-suite executives. Conversely, recent institutional investor activity shows a net positive inflow, with 91 firms adding to their positions versus 43 reducing, and notable new multi-million dollar stakes taken by entities like Great Point Partners and AIGH Capital Management. This divergence between insider sentiment and some institutional buying, set against a drug with a narrow indication and significant safety warnings, presents a complex picture for AKBA, reflected in a mildly negative overall sentiment score (-0.3).

Key Decisions for Investors

• Investors should carefully evaluate Vafseo's commercial prospects, noting its narrow FDA approval for dialysis-dependent CKD patients and the significant cardiovascular safety concerns and boxed warning which may limit physician adoption and market size.
• The pronounced insider selling activity by top executives, including the CEO, warrants considerable caution and should be weighed against the recent surge in institutional buying, which may indicate a speculative or value-based interest by some funds.
• Monitor Vafseo's U.S. sales uptake in its approved indication, any further clarification or data on its safety profile, and how prescribing physicians perceive the benefit-risk profile, particularly given the MACE signals in broader patient populations from past trials.
• Consider the highly restrictive label and the explicit non-indication for non-dialysis CKD patients as a primary constraint on Vafseo's long-term revenue potential, despite its approval in 37 countries.